ARMO BioSciences (ARMO) is planning to raise $100 million in an IPO on Friday, January 26th, IPO Scoop reports. The company plans to issue 6,700,000 shares at $14.00-$16.00 per share.

The company has a market cap of $426.2 million.

Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Baird was co-manager.

ARMO BioSciences provided the following description of their company for its IPO: ”  We are a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. Our vision is to improve and prolong the lives of cancer patients by advancing and expanding the field of immuno-oncology through novel combinations and treatment sequences of our pipeline products with standard of care chemotherapies and checkpoint inhibitors or with other emerging immunotherapies that elicit complementary and synergistic treatment effects.   “.

ARMO BioSciences was founded in 2010 and has 21 employees. The company is located at 575 Chesapeake Drive, Redwood City, CA 94063, US and can be reached via phone at (650) 779-5075 or on the web at

Receive News & Ratings for ARMO BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARMO BioSciences and related companies with's FREE daily email newsletter.